drug

Drug companies slash thousands of jobs as new drugs fail, old patents expire

Friday, January 20, 2012 by: Jonathan Benson, staff writer
Tags: drug companies, downsizing, patents

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Malaysia Airlines Flight 370 now clearly a government cover-up: All evidence contradicts official story
White House admits staging fake vaccination operation to gather DNA from the public
10 other companies that use the same Subway yoga mat chemical in their buns
High-dose vitamin C injections shown to annihilate cancer
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
U.S. treating meat with ammonia, bleach and antibiotics to kill the '24-hour sickness'
Ben and Jerry's switches to non-GMO, Fair Trade ice cream ingredients
Battle for humanity nearly lost: global food supply deliberately engineered to end life, not nourish it
Russia taking McDonald's to court, threatens countrywide shutdown
Diet soda, aspartame linked to premature deaths in women
Cannabis kicks Lyme disease to the curb
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
Harvard research links fluoridated water to ADHD, mental disorders
Delicious
(NaturalNews) For years, many major drug companies have had it made with a steady stream of new "blockbuster" drugs that carry with them 20-year patents, ensuring years of billion-dollar profits. But many of these patents are now expiring, and these same drug companies have largely failed to concoct successful new drugs to take their place, which has resulted in widespread employee layoffs and major downsizing within the drug industry.

According to a recent Reuters report, drug giant Novartis AG is laying off roughly 2,000 of its sales force employees due to its largest wave of patent expirations. AstraZeneca, another major drug company, announced recently that it is laying off 25 percent of its US sales force. And Sanofi SA announced late last year that it will make cuts in its sales and research and development (R&D) divisions as the company consolidates all its North American facilities (http://online.wsj.com/article/SB10001424052970203716204577013930254809686.html).

To be clear, all three of these companies still rake in billions of dollars every year for drugs they produce and sell. But now that times are getting a little bit tough, they are rapidly eliminating their US and North American workforces, consolidating their corporate structures, and unscrupulously continuing to export jobs overseas to countries where more profits can be made.

About a year ago, data compiled by EvaluatePharma, an industry analysis group, revealed that more than $15 billion worth of drug patents were set to expire last year. And by 2016, a whopping $133 billion worth of drug patents will expire, which means that generic drug manufacturers will swoop in and break up the monopoly by selling those drugs at much lower, and more appropriate, prices (http://www.naturalnews.com/031234_drug_patents.html).

The only way the major drug players are able to maintain multi-billion dollar a year profits, you see, is by innovating new drugs, buying their approval from the US Food and Drug Administration (FDA), and watching the cash flow in for 20-or-so years while they work on producing a new set of drugs. It is a continuous cycle that generates obscene profits for the drug industry at the expense of public health.

Besides just a decrease in the number of new drug developments, major drug makers are facing great losses with the few they have already released, as studies often show them to be useless or even harmful. Novartis' blood pressure drug Rasilez, for instance, was recently found to make patients' condition worse rather than better. As a result, the company's profit projections for Rasilez have had to be readjusted, and may potentially have to be readjusted again if the drug is pulled from the market.

Sources for this article include:

http://www.reuters.com/article/2012/01/13/us-novartis-idUSTRE80C0EB20120113

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.